ArticleBMC cancer2026

Study protocol of the C-SOLVE (JACCRO GC-12) trial; a randomized, non-comparative phase II trial of CapeOX or SOX plus zolbetuximab in HER2-negative, CLDN18.2-positive unresectable advanced gastric or esophagogastric junction cancer.

Satoshi Yuki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.